Logo image of TPST

TEMPEST THERAPEUTICS INC (TPST) Stock Fundamental Analysis

NASDAQ:TPST - Nasdaq - US87978U1088 - Common Stock - Currency: USD

7.28  +0.03 (+0.41%)

Fundamental Rating

2

Overall TPST gets a fundamental rating of 2 out of 10. We evaluated TPST against 568 industry peers in the Biotechnology industry. While TPST seems to be doing ok healthwise, there are quite some concerns on its profitability. TPST has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TPST has reported negative net income.
In the past year TPST has reported a negative cash flow from operations.
TPST had negative earnings in each of the past 5 years.
In the past 5 years TPST always reported negative operating cash flow.
TPST Yearly Net Income VS EBIT VS OCF VS FCFTPST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

TPST's Return On Assets of -100.86% is on the low side compared to the rest of the industry. TPST is outperformed by 76.41% of its industry peers.
Looking at the Return On Equity, with a value of -218.78%, TPST is doing worse than 70.60% of the companies in the same industry.
Industry RankSector Rank
ROA -100.86%
ROE -218.78%
ROIC N/A
ROA(3y)-78.49%
ROA(5y)-71.6%
ROE(3y)-175.41%
ROE(5y)-142.93%
ROIC(3y)N/A
ROIC(5y)N/A
TPST Yearly ROA, ROE, ROICTPST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

TPST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TPST Yearly Profit, Operating, Gross MarginsTPST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, TPST has more shares outstanding
Compared to 5 years ago, TPST has more shares outstanding
Compared to 1 year ago, TPST has an improved debt to assets ratio.
TPST Yearly Shares OutstandingTPST Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
TPST Yearly Total Debt VS Total AssetsTPST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -9.14, we must say that TPST is in the distress zone and has some risk of bankruptcy.
TPST has a Altman-Z score of -9.14. This is in the lower half of the industry: TPST underperforms 71.30% of its industry peers.
TPST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.14
ROIC/WACCN/A
WACCN/A
TPST Yearly LT Debt VS Equity VS FCFTPST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.21 indicates that TPST has no problem at all paying its short term obligations.
TPST has a Current ratio of 2.21. This is in the lower half of the industry: TPST underperforms 72.71% of its industry peers.
A Quick Ratio of 2.21 indicates that TPST has no problem at all paying its short term obligations.
TPST has a Quick ratio of 2.21. This is in the lower half of the industry: TPST underperforms 71.13% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
TPST Yearly Current Assets VS Current LiabilitesTPST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

TPST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -420.00%.
EPS 1Y (TTM)-420%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-960.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TPST will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.90% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-49.81%
EPS Next 2Y-35.84%
EPS Next 3Y-35.82%
EPS Next 5Y8.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TPST Yearly Revenue VS EstimatesTPST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2028 2030 2031 2032 50M 100M 150M 200M
TPST Yearly EPS VS EstimatesTPST Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2K -4K -6K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TPST. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TPST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TPST Price Earnings VS Forward Price EarningsTPST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TPST Per share dataTPST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

A cheap valuation may be justified as TPST's earnings are expected to decrease with -35.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.84%
EPS Next 3Y-35.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TPST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEMPEST THERAPEUTICS INC

NASDAQ:TPST (4/17/2025, 8:00:00 PM)

7.28

+0.03 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners15.54%
Inst Owner Change0%
Ins Owners0.17%
Ins Owner Change0%
Market Cap25.63M
Analysts85.45
Price TargetN/A
Short Float %4.9%
Short Ratio2.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.82%
Min EPS beat(2)-20.6%
Max EPS beat(2)-11.04%
EPS beat(4)1
Avg EPS beat(4)-7.03%
Min EPS beat(4)-20.6%
Max EPS beat(4)5.68%
EPS beat(8)4
Avg EPS beat(8)0.86%
EPS beat(12)7
Avg EPS beat(12)4.78%
EPS beat(16)8
Avg EPS beat(16)-45.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-54.03%
PT rev (3m)-47.22%
EPS NQ rev (1m)-1279.2%
EPS NQ rev (3m)-1164.29%
EPS NY rev (1m)-1333.07%
EPS NY rev (3m)-1333.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-10.14
EYN/A
EPS(NY)-15.19
Fwd EYN/A
FCF(TTM)-9.51
FCFYN/A
OCF(TTM)-9.38
OCFYN/A
SpS0
BVpS5.43
TBVpS5.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.86%
ROE -218.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.49%
ROA(5y)-71.6%
ROE(3y)-175.41%
ROE(5y)-142.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -9.14
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.31%
Cap/Depr(5y)60.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-420%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-960.53%
EPS Next Y-49.81%
EPS Next 2Y-35.84%
EPS Next 3Y-35.82%
EPS Next 5Y8.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-110.06%
EBIT Next 3Y-49.26%
EBIT Next 5Y-44.07%
FCF growth 1Y-21.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.73%
OCF growth 3YN/A
OCF growth 5YN/A